Aurobindo Pharma gains on USFDA nod for gastroesophageal reflux drug

The USFDA nod is for Esomeprazole Magnesium delayed-release capsules USP in dosages of 20mg and 40mg.

Shares of Aurobindo Pharma were up nearly 2% at Rs 781 after the company announced that it has received approval from the USFDA to manufacture and market Esomeprazole Magnesium delayed-release capsules USP in dosages of 20mg and 40mg.

Esomeprazole Magnesium delayed-release capsules is bioequivalent and therapeutically equivalent to the reference listed drug product Nexium delayed-release capsules, 20mg and 40mg, of AstraZeneca Pharmaceuticals LP, the comany said in a release.

Esomeprazole Magnesium delayed-release capsules is used in the treatment of gastroesophageal reflux disease, the release added.

The stock opened at Rs 767 and touched a high of Rs 789. At 2:20pm, over 1.7 million shares were traded on both the stock exchanges.